We are pleased to announce that the latest QIAGEN Clinical Insight (QCI) Interpret software release is now available. Expanding on the software’s current capabilities, the update adds new features and guidelines to enhance the interpretation and reporting of genomic variants.
Immediately determine and filter to genes implicated in hereditary diseases that are most relevant to report with Strong or Definitive Clinical Validity. With this new features, users can quickly review clinical validity statements that summarize the evidence supporting the strength of a gene-disease relationship. Gene-disease relationships include those determined by the ClinGen Gene Curation Working Group and are extended to cover all gene-diseases via computing clinical validity based on the ClinGen classification guidelines using the expert-curated and integrated evidence in the QIAGEN Knowledge Base.
Interactively add and remove symptoms (and diseases) in hereditary workflows at anytime. With this new feature, users can rapidly adjust symptoms if more case information becomes available. The ranking of candidate diseases for variants in the Phenotype Driven Ranking (PDR) view is dynamically updated based on the updated symptoms.
Review curated evidence supporting each candidate disease for a case in the hereditary workflow with the Phenotype Network—a new feature that provides a summary of the gene-disease clinical validity and a visual diagram of the paths via QIAGEN Knowledge Base relationships from symptoms provided for a case to a candidate disease. This enables users to quickly and interactively review relationship-specific supporting evidence, including source citations.
The NICE Guidelines for Oncology are now available for clinical reporting in QCI Interpret and QCI Interpret One. QIAGEN’s expert guideline curation provides the most up-to-date evidence-based guidance from NICE to support treatment selection for patients. NICE guideline recommendations are also used to support the computed AMP/ASCO/CAP variant classification to ensure relevant variants are indicated for review.
For information about the latest release, including the full release notes, please contact your QIAGEN Digital Insights account manager or customer support at ts-bioinformatics@qiagen.com.
We also invite you to watch our on-demand webinar, "Overcoming Challenges of Copy Number Variant (CNV) Interpretation," where our experts provide a virtual demonstration of QCI Interpret, showing how users can quickly evaluate CNVs and compute their pathogenicity using the new ACMG/ClinGen guidelines.
Visit our QCI Interpret webpage to request a complimentary demonstration.
We're pleased to announce that our newest clinical NGS variant interpretation and reporting solution is now available in Europe.
QCI Interpret One is clinical decision support software integrated with professional variant interpretation services that enables rapid, evidence-based reporting of oncology NGS tests at scale.
Connected to the world’s most comprehensive, manually curated knowledge base that is updated weekly, QCI Interpret One dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with full transparency.
Users get access to over 200,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and regional clinical trials, based on the lab's regional labels and guidelines.
For US users, QCI Interpret One generates reports according to FDA/NCCN/WHO guidelines for therapeutic, prognostic, and diagnostic actionability. View Sample Report.
For EMEA users, QCI Interpret One generates reports according to EMA/ESMO/ELN/WHO guidelines for therapeutic, prognostic, and diagnostic actionability. View Sample Report.
Learn more about QCI Interpret One in our upcoming live webinar, Thursday, October 15 at 10 AM EST | 4 PM CET. Our experts will provide an overview of the solution, as well as demonstrate how QCI Interpret One can help clinical laboratories grow caseload volume, accelerate test turnaround time, and deliver oncologist-ready reports without requiring additional staff.
Next-generation sequencing (NGS) has transformed the field of oncology. Early successes in identifying and targeting oncogenic drivers of solid tumors have set the foundation for genomics guided precision medicine; but, for hematological malignancies, the path to precision medicine is a lot more complex.
Within the hematologic oncology space, there is a spectrum of biologically related, but clinically heterogeneous diseases. In part, the differences between patients are driven by the particular combination of genetic mutations each disease acquires during its evolution. To effectively treat and manage myeloid malignancies, hematologist oncologists need highly parallel, highly sensitive assays that (1) enable the simultaneous analysis of multiple genes and (2) are coupled with indication-specific bioinformatic pipelines that provide information on disease classification, prognostication, treatment selection, and monitoring.
In this application note, we discuss the importance of streamlined clinical NGS workflows within the hematologic-oncology space. Learn how to develop a robust, automated, and streamlined NGS analysis pipeline for the interpretation and reporting of genomic alterations associated with hematological malignancies.
